Concepedia

Author

Bahru Habtemariam

Alnylam Pharmaceuticals (United States)

Also Known As

B Habtemariam, B. Habtemariam, Bahru A Habtemariam, Bahru A. Habtemariam, Bahru Habtemariam, Bruck Habtemariam

40

Publications

2.7K

Citations

17

H-Index

28

Concepts

All Affiliations

Alnylam Pharmaceuticals (United States)Hospices Civils de LyonShaare Zedek Medical CenterMayo ClinicCenter for Drug Evaluation and Research
BH

About

Bahru Habtemariam is an author at Alnylam Pharmaceuticals (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

746

2

Health Sciences

3

3

440

3

Diabetes

1

1

44

4

Epidemiology

1

1

44

5

Hepatology

1

1

99

Bahru Habtemariam

×

16

Publications

2.2K

Citations

15

H-Index

YearCitations

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

Robert Q. Le, Liang Li, Weishi Yuan,

The Oncologist

2018

859

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

Thomas M. Herndon, Albert Deisseroth, Edvardas Kaminskas,

Clinical Cancer Research

2013

240

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Angelo de Claro, Karen M. McGinn, Virginia E. Kwitkowski,

Clinical Cancer Research

2012

207

Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects

Bahru Habtemariam, Verena Karsten, Husain Attarwala,

Clinical Pharmacology & Therapeutics

2020

159

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

R. Angelo de Claro, Karen M. McGinn, Nicole Verdun,

Clinical Cancer Research

2015

156

Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria

Sagar Agarwal, Amy Simon, Varun Goel,

Clinical Pharmacology & Therapeutics

2020

99

Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial

Mini Michael, Jaap W. Groothoff, Hadas Shasha‐Lavsky,

American Journal of Kidney Diseases

2022

79

Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1

Yaacov Frishberg, Georges Deschênes, Jaap W. Groothoff,

Clinical Journal of the American Society of Nephrology

2021

78

Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria

Prajakta Badri, Xuemin Jiang, Anna Borodovsky,

Clinical Pharmacokinetics

2020

73

Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children

David J. Sas, Daniella Magen, Wesley Hayes,

Genetics in Medicine

2021

72

Page 1